# 审计整改报告

审计方：新博研桥（客户）

审计时间：2024年8月14~15日

编制/日期：绿假 2025.04.22

审核/日期：2015.04.22

审核/日期：  ${2025.04.22}$

批准/日期： 招要2021年医疗保健

长

根据贵公司2024年8月14~15日现场审核内容及20240924Adult report审计报告，

我公司根据要求进行了根本原因分析，采取了相应纠正、纠正措施、预防措施，现报告如下：

<table><tr><td>序号</td><td>不符合描述</td><td>纠正措施</td><td>预防措施</td></tr><tr><td>1</td><td>Quality System/Quality Policy / Quality ManualThe quality manual does not identify the responsibilities of validation approvals, batch approvals, COA/COC approvals. QR/MR - Quality Representative (ALEX) does not review OR approval for the design controls, supplier audits, software implementations, regulatory reporting; instead QP-Quality Person (KAYLA) approves the Quality documents related to medical device quality, safety, customer satisfaction and continuous improvement.</td><td rowspan="2">升版《质量手册》1、增加验证批准、批批准、COA/COC批准的职责与权限;2、增加RA职责3、修改组织架构图,增加RA4、明确QR职责见附件1</td><td rowspan="2">N/A</td></tr><tr><td>2</td><td>Quality System/Quality Policy / Quality ManualThe organization charts do not represent RA department, where RA director (Grace Xue) is available at site.</td></tr><tr><td colspan="4">完成日期:2025-01-03</td></tr><tr><td>3</td><td>Quality System/Quality Policy / Quality ManualWith respect Pen-Injector Device (manufactured for LBE Pharma Tech), ISO certificate scope limited for design & manufacturing only, not for sales or distribution, which is not compliant with LBE contract manufacturer scope for combination product registration and approvals.</td><td>1. 出具说明:默认生产范围即包括销售部分,由SGS盖章,见附件2。2. 在2025年4月,SGS年审时,向SGS提出证书范围增加“销售”,见附件3</td><td>N/A</td></tr><tr><td colspan="4">完成日期:2025-01-22</td></tr><tr><td>4</td><td>Quality / Management ReviewThe Management review procedure not in-line with quality policy/quality objectives such as; no review for communication to customers, No review of shipping information, no review of OOS / QC testing monitoring.</td><td>1、升版质量手册,更换管理者代表,见附件12、增加管理者代表对ISO13485体系的培训,见附件43、增加管理者代表对《管理评审控制程序》的培训,见附件</td><td>4、按照《管理评审控制程序》实施完整的管理评审,见附件5</td></tr><tr><td></td><td></td><td>5</td><td></td></tr><tr><td colspan="4">完成日期:2025-02-21</td></tr><tr><td>5</td><td>Internal AuditsInternal Audit procedure does not define how to qualify auditors (No criteria is defined with respect to training, medical device working experience, education, past audit experience, auditor performance and re-qualification of auditors) and list of qualified auditors is not available at site.</td><td>1、升版QP25《内部审核管理程序》明确规定内审员资质,每年需要培训课程,内审员资格重新认证,见附件6</td><td>2、对升版的内部审核控制程序进行培训与考核,见附件5</td></tr><tr><td colspan="4">完成日期:2025-01-02</td></tr><tr><td>6</td><td>Corrective and Preventive Action (CAPA)In CAPA procedure, the time limit/target date for the closure of a CAPA is defined in CAPA form, but no CAPA extension criteria is defined. No detailed process of CAPA effectiveness check is defined.</td><td>1.升版纠正措施与预防措施管理程序,增加CAPA的触发与扩展条件,增加纠正和预防措施实施的有效性验证方法,见附件7。</td><td>2.对升版的纠正措施与预防措施管理程序进行培训与考核,见附件8</td></tr><tr><td colspan="4">完成日期:2024-12-10</td></tr><tr><td>7</td><td>Adverse ReportingAdverse Reporting procedure is inadequate with following below:·No reporting process flowchart·No reporting events are listed; No LOG/Register for follow-up/record/status is available·No internal timeline for reporting·No instructions how to fill the regulatory reporting forms online or offline; such as FORM 3500A</td><td>1.针对不良事件在欧洲、中国、美国的法规处理要求,升版《QP24 不良事件监测和再评价控制程序》程序文件,1.增加流程图,2.收集不良事件,每个季度更新收集信息,3.定义内部上报流程,4.规定3500A表格的填报要求,见附件9。</td><td>2.增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的培训,见附件43.3500表单已在体系内完成管控,见附件50</td></tr><tr><td colspan="4">完成日期:2025-01-10</td></tr><tr><td>8</td><td>ComplaintComplaints procedure is inadequate with following below:·No timeline for closure of complaints·No feedback or no notification to customers or regulatory agency</td><td>针对客户抱怨在欧洲、中国、美国的法规处理要求,升版《QP22 客户抱怨管理程序》程序文件,见附件10</td><td>增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的培训,见</td></tr><tr><td></td><td>·No CAPA is initiated for complaints
·No investigation in order to determine potential effect and root cause</td><td></td><td>附件4</td></tr><tr><td colspan="4">完成日期:2024-11-30</td></tr><tr><td>9</td><td>Recalls
Recall procedure is inadequate with following below:
·No verification process for recall program effectiveness (weather recall process is reliable or not).
·No CAPA is initiated for recall</td><td>1.针对召回在欧洲、中国、美国的法规处理要求,升版《QP30产品召回管理程序》程序文件,见附件11
2.后续升版《QP30产品召回管理程序》,增加模拟召回内容</td><td>3.增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的培训,见附件4</td></tr><tr><td colspan="4">完成日期:</td></tr><tr><td>10</td><td>Risk management
Risk management procedure is inadequate with following below:
·Risk management does not compliant with ISO 14971 Standard
·No Risk management process flowchart
·The Scope of Risk Management is not available
·No FMEA tools are used for the risk management</td><td>改版QP09风险管理控制程序,见附件12,风险管理计划中增加相应FMEA工具的使用,见附件53</td><td>N/A</td></tr><tr><td colspan="4">完成日期:2025-02-11</td></tr><tr><td>11</td><td>Change control
No change control procedure is available at site for the changes related to process, facility, supplier, equipment, materials, key personnel and new project.</td><td>1.升版《设计变更作业准则》,见附件13</td><td>2.增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的培训,见附件4</td></tr><tr><td colspan="4">完成日期:2025-02-11</td></tr><tr><td>12</td><td>Deviations
No process deviations procedure is available at site.</td><td>1.新增管理文件,见附件14</td><td>2.增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的标准培训见附件4</td></tr><tr><td colspan="4">完成日期:2024-11-27</td></tr><tr><td>13</td><td>InvestigationNo procedure for handling investigation is available at site.</td><td>1.升版程序文件,增加调查的要求,见附件152.后续增加《调查管理规定》</td><td>2.增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的标准培训,见附件4</td></tr><tr><td colspan="4">完成日期:未完成,按要求新增文件,5月内完成</td></tr><tr><td>14</td><td>Product ReleaseNo procedure for product release is available at site.</td><td>已有相关文件,升版文件规定,见附件16</td><td>N/A</td></tr><tr><td colspan="4">完成日期:2024-11-27</td></tr><tr><td>15</td><td>Quality Review (for contract manufacturing products)No procedure is available for Quality Review for contract manufacturing products which, includes results of in-process controls (IPCs), raw materials and finished product testing, deviations, changes, CAPA, complaints, returned products, process air monitoring, stability tests, validation status, OOSs, and supplier evaluations.</td><td>1.新增管理文件,见附件17</td><td>2.增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的标准培训,见附件4</td></tr><tr><td colspan="4">完成日期:2024-12-10</td></tr><tr><td>16</td><td>Test MethodsDuring QC lab tour, it was noted that;·No audit trail function is available in VMS software used image testing machine. The same observation found in Magnum software used in tension testing machine·No data integrity compliance for the data stored in VMS software & Magnum software (no controls on data back-up, data modification, data deletion, data transfer, data storage).·No controls on Date/Time on every PC used for testing in QC Lab (date & time can be modified).·No minimum verification (daily verification) is performed on balance (only 200mg standard</td><td>1.升版QW-QD-11万濠影像测量仪操作规程与QW-QD-13美特斯万能试验机操作规程,增加记录原始数据的功能,见附件182.增加实验室电脑分级管理文件,增加数据备份、数据修改、数据存储、定期校准时间等要求,见附件19。因人员缺失,暂未能按要求实施,持</td><td>8.对升版的QW-QD-10岛津AUY220型电子天平操作规程进行培训与考核,见附件249.对建立的留样管理规定进行培训与考核,见附件2510.增加对增加对GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规</td></tr><tr><td></td><td>weights are used for daily verification)·No temperature monitoring in Retention sample room·No records are available for retention sample storage·No rationale for retention sample volume·Stability chamber - 4620 mapping report is adequate with below;Mapping is performed for empty load condition;full loading condition is not carried out.No conclusion was addressed in mapping report</td><td>续改进。3.升版 QW-QD-10岛津 AUY220 型电子天平操作规程,增加小量程每日验证的要求,见附件 204.采购 0.01g、0.1g、1.0g、10.0g 等小量程砝码并计量合格,见附件 205.建立留样管理规定,增加留样管理要求,见附件 216.升版 QW-QD-14宏展恒温恒湿箱操作规程,增加计量点、计量方式的要求,见附件 22。恒温箱后续进行温度分布验证7.升版监视和测量设备管理程序,增加对计量的结果进行符合性判断的要求,并增加相关记录,见附件 23</td><td>的要求的标准培训,见附件 411.对升版的监视和测量设备管理程序进行培训与考核,见附件 2612.留样记录是电子台账登记,现场留样样品有货位卡。电子台账根据需要纸质打印,见附件 49</td></tr><tr><td colspan="4">完成日期:持续改进</td></tr><tr><td>17</td><td>DHFDuring DHF review, it was found that;·No conclusion was addressed in Design FMEA (risk management) document·Dose Accuracy Performance testing - No partial dosage issue is challenged; no alarms or indication notifies to user for partial dosage·RMP is inadequate with Acceptance criteriaTesting methodSampling plan for each test</td><td>1.FMEA 表单增加审核、批准栏位,见附件 27,FMEA 表单不会形成总结性的结论,结论会在风险管理报告中呈现2.Simject 自动注射笔设计为一次使用,没有多次使用的设计,因此无需进行部分计量测试或进行</td><td>4.本公司按照ISO10993.1-2018对 simject 产品进行生物学评价规划,产品为短暂接触完好皮肤的表面医疗器械产品,通过步骤判定,已经建立了建立了材料的安全使用史,且物理性能没有改变,因</td></tr><tr><td></td><td>·Biocompatibility plan does not includeExtractables testing and Adsorpables testing
·Human factors study & Usability test is performed without human user group</td><td>警示、通知3. RMP风险管理计划为设计开发输入阶段形成的,旨在对产品各阶段需要进行风险管理的活动进行识别,而测试项目、测试标准与测试取样计划为设计开发验证阶段才能最终确定,因此,RPM计划中不会包含此部分内容。同时,ISO14971标准中也未有相应规定</td><td>此无需按照ISO10993-18进行可提取物的化学分析。
5.本公司按照法规要求进行可用性工程评估,已包含人为因素。</td></tr><tr><td colspan="4">完成日期:2025-02-11</td></tr><tr><td>18</td><td>Personnel & Hygiene
Inadequate practices were observed during the site tour regarding as below;
·Consumption of food near packaging material storage
·Personnel in the process areas (CNC) does not wear shoe cover (no protection from outside dirt)
·Personnel in contact with the product in process areas does not wear hand gloves, mask or safety googles (no protection from hand contamination and hair)</td><td>1.重新划分休息区域和仓储区域,见附件28
2.升版《着装管理规定》,增加相关着装要求,见附件29</td><td>3.对升版《着装管理规定》进行培训与考核,见附件30</td></tr><tr><td colspan="4">完成日期:2024-12-12</td></tr><tr><td>19</td><td>Training procedure is inadequate with following below:·No Trainings on device defects (either during performance of their specific jobs or Personnel who perform verification and validation activities)·No criteria for qualification of quality representative/Authorised person/quality person·No Re-training policy is available·Training effectiveness is not measured through a paper exam for GMP/ISO trainings and a practical operation test for critical</td><td>1.建立《岗位职责与任职条件管理规定》，增加管代的岗位职责与任职条件，见附件312.升版人力资源管理程序，规定关键岗位人员持证上岗的要求，规定年度复评价的内容，对各个培训建立详细的考核要求，见附件32</td><td>3.《岗位职责与任职条件管理规定》中，对其他影响质量的岗位进行岗位职责与任职条件的规定，见附件314.对《岗位职责与任职条件管理规定》进行培训与考核，见附件335.对升版的人力资源管理程序进行培训与考核，见附件33</td></tr><tr><td colspan="4">完成日期：2024-11-20</td></tr><tr><td>20</td><td>During facility tour, it was noted that;·Warehouse area is not controlled with entry/exit·No separate area for Reject and reject materials are easily accessible (no control on reject area with cage or locked to avoid mix-ups)</td><td>1升版仓库管理制度，规定仓库物料的防护要求，以及不合格品的存放要求，见附件342.已建设独立密闭空间以存放不合格品，按仓库管理制度划分仓库区域，见附件35</td><td>3.对升版的仓库管理制度进行培训与考核，见附件364.对仓库管理人员进行GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的培训，见附件4</td></tr><tr><td colspan="4">完成日期：2024-12-19</td></tr><tr><td>21</td><td>During facility tour, it was noted that; Compressed air unit is installed within warehouse, where materials are stored next to it. No oil filters or particle filters are installed prior to manufacturing equipment to avoid particle or oil contamination.</td><td>1.建设独立密闭空间，完善工作环境优化，见附件372.建立设备操作规程，规定滤芯更换时机，见附件38</td><td>3.对生产管理人员进行GBT42061-2022idtISO 13485:2016医疗器械质量管理体系用于法规的要求的标准培训，见附件4</td></tr><tr><td colspan="4">完成日期：2024-12-20</td></tr><tr><td>22</td><td>During Testing report review, it was found that;</td><td>1.升版实验室内需要</td><td>3.对升版的设备操</td></tr><tr><td></td><td>·The testing reports does not include raw data
·No signatures (review & approval) are found in the testing reports</td><td>保留原始数据的设备操作指导书，增加如何保留测试原始数据的要求，见附件18
2.修改报告格式，记录增加复核人、报告增加批准人，见附件39</td><td>作规程进行培训，见附件24</td></tr><tr><td colspan="4">完成日期：2024-12-10</td></tr><tr><td>23</td><td>During facility tour, it was noted that;
·MES - Material enterprise system commercial software is not validated and no controls in place.</td><td>1.根据公司新版计算机软件确认控制程序规定，用于财务结算的计算机软件系统，无需对其进行软件确认，见附件51</td><td>2.本公司ERP系统根据公司财务运行要求，仅需验证其功能是否能够实现，见附件40</td></tr><tr><td colspan="4">完成日期：2024-12-31</td></tr><tr><td>24</td><td>During procedure review, it was found that;
·No defined frequency of onsite audit for Key suppliers – A & B
·No Qualified auditor list is in place</td><td>1、升版QP13供应商评鉴管理程序
①明确现场审核频率
②需参与的审核部门
③审核人员的资质，见附件41
2.本公司依据《医疗器械生产企业供应商审核指南》建立供应商评鉴管理程序，法规中未明确要求需要建立审核员清单，且本公司程序文件中也未形成相关规定</td><td>3.对升版的文件进行培训与考核，见附件36</td></tr><tr><td colspan="2">完成日期：2024-12-19</td><td colspan="2"></td></tr><tr><td>25</td><td>During facility tour, it was noted that;
·No rationale for 100% check for Appearance (Material appearance testing)
·No Incoming testing is performed on some parts</td><td>1.提供受控的QW-QD-08抽样规程、进货检验记录等文件，证明未进行</td><td>4.对研发人员进行GBT42061-2022idtISO 13485:2016医疗器械质量管</td></tr><tr><td></td><td>(customer OQC testing results are accepted instead of IQC testing) observed in material warehouse.
·No Mold design controls are in place (as mold design is outsource).</td><td>100%外观检验。见附件42
2.增加检验人员对于《原材料检验规程》与《标识和可追溯性的管理程序》的培训与考核,见附件25
3.已有《模具开发分类编码保养报废作业指导》,见附件43</td><td>理体系用于法规的要求的标准培训,见附件4
5.本公司进货检验记录单截图,见附件52</td></tr><tr><td colspan="4">完成日期:2024-12-10</td></tr><tr><td>26</td><td>During facility tour, it was noted that;
·No procedure is in place for handling process materials in processing areas
·No designated areas for process materials storage are available in process assembly room to prevent mix-up
·Production Line Design is not followed (sequential operations for each assembly line process-step-by-step assembly of products)</td><td>1.新建《生产车间作业要求》,增加SOP挂于相应的生产条线现场的要求.明确原材料与成品区域划分的要求及产线布局图,见附件44</td><td>2.对新建的《生产车间作业要求》进行培训与考核,见附件45
3.增加生产管理人员GBT42061-2022idt ISO 13485:2016医疗器械质量管理体系用于法规的要求的标准培训,见附件4</td></tr><tr><td colspan="4">完成日期:2025-01-06</td></tr><tr><td>27</td><td>During facility tour, it was noted that;
·No procedure is in place for handling standard golden sample
·No FAI (first article inspection) sample verification is performed with standard golden sample</td><td>1.已建立首件检验计划&报告空白模板,见附件46
2.对检验员进行过程控制和产品检验规程的培训与考核,见附件25</td><td>3.后续受控simject FAI样件</td></tr><tr><td colspan="4">完成日期:后续改进</td></tr><tr><td>28</td><td>Design & development
During Design Change review, it was found that, no validation is performed for FEI-SHU APP used for design changes.</td><td>1.提供飞书截图证明,飞书功能中不包含设计变更的功能,见附件47</td><td>N/A</td></tr><tr><td></td><td></td><td>2.提供设计变更纸质记录，证明未使用飞书进行变更申请，见附件48</td><td></td></tr><tr><td colspan="4">完成日期：2024-12-10</td></tr></table>
